Loading ...
to prevent the formation of new blood vessels , thereby stopping or slowing the growth or spread of tumours(passive) are designedAngiogenesis inhibitors
to prevent the formation of new blood vessels , thereby stopping or slowing the growth or spread of tumors(passive) are designedAngiogenesis inhibitors
1980 Deaths from HIV / AIDS , which was relatively unknown in 1980 ... biopharmaceutical researchersdiscoveredprotease inhibitors
recently(passive) were ... discovered/ AKT inhibitors
lead candidate ACH-1625 ( now known as sovaprevir(passive) led byAchillion ’s protease inhibitors
pivotal trial AstraZeneca EVP : Brexit is hindering our hiring Forge Therapeutics , Evotec launch platformto discovermetalloenzyme inhibitors
from natural sources , including tree bark , fungi , shark muscle and cartilage , sea coral , green tea , and herbs ( licorice , ginseng , cumin , garlic(passive) have been discoveredAngiogenesis inhibitors
to stop those signals from being received and come in various forms(passive) are designedAngiogenesis inhibitors
based on dioxabicyclo[3.2.1 ] octane with the aim to search new lead molecule(passive) were designedSGLT2 inhibitors
to help manage blood sugar in people living with type 2 diabetes(passive) are designedSGLT2 inhibitors
to prevent the formation of new blood vessels such action may stop or slow the growth and spread of tumors(passive) are designedAngiogenesis inhibitors
protein - protein interactions ... extremely challengingto designHIF-1α inhibitors
to reduce hyperglycaemia in people with diabetes by competitive inhibition of SGLT2 transport system in the kidney(passive) were initially designedSGLT2 inhibitors
to overcome a cancer cell(passive) are designedPARP inhibitors
Inc. Boceprevir ( Victrelis ) , from the oral α - ketoamide class of slow - binding reversible hepatitis C viruscreatesHCV)-NS3 protease inhibitors
to be screened against the Molecular Libraries Small Molecule Repository ( MLSMRto discoverTDP-43 inhibitors
Donahue Timothy R Histoneprovokedeacetylase inhibitors
a long - running research programme at the ICRto discoverMPS1 inhibitors
Crystal structures of constitutive nitric oxide synthases in complex with de novodesignedinhibitors
to help the kidneys reduce the level of sugar in the bloodstream(passive) are designedSGLT2 inhibitors
to stop the repair process in cancer cells(passive) are designedPARP inhibitors
to target cancers that already have existing defects in DNA repairs(passive) are designedPARP inhibitors
other groups for cancer treatment in patients.47 - 50(passive) have been ... discovered byEzh2-specific inhibitors
to attack tumors by depriving cancer cells of their blood(passive) are designedAngiogenesis inhibitors
to stop the proteasomes from recycling proteins inside cancer cells(passive) are designedProteasome inhibitors
to help keep blood sugar low by working on the way the kidneys process glucose(passive) are designedSGLT2 inhibitors
to help reduce cholesterol levels while at the same time significantly decreasing the risk of heart attacks and strokes(passive) are designedinhibitors
Scientific data on the role of PI3 K , BTK kinase in cancer and PI3 Khave ledBTKs inhibitors
to help reduce blood sugar levels by preventing the reabsorption of glucose from the kidneys back into the blood so that more glucose is excreted in the urine(passive) are designedSGLT2 inhibitors
to help the body remove blood sugar from the bloodstream of type 2 diabetes patients by inducing the kidneys to secrete this sugar through urine(passive) are designedSGLT2 inhibitors
around the cleavage site of the a - chain sequence of Type II collagen ( Johnson et al . , J. Enzym(passive) have also been designedCollagenase inhibitors
Most recent papers with the keyword linker | Read by QxMD https://www.readbyqxmd.com/read/29055186/designed-inhibitors-with-hetero-linkers-for-gastric-proton-pump-h-k-atpase-steered-molecular-dynamics-and-metadynamics-studiesDesignedinhibitors
Starting from gene expression tumor profiling , and given the presence of epidermal growth factor ( EGF ) in 25 - 30 % of gastric cancer as well as the positive experience obtained in the metastatic colorectal cancer ( mCRC )settingInhibitors
to block certain enzymes the virus needs to replicate(passive) are designedProtease inhibitors
with the aim of developing analgesic and antihypertensive agents that act by preventing neprilysin 's activity against signaling peptides such as enkephalins , substance P , endothelin , and atrial natriuretic peptide(passive) have been designedInhibitors Inhibitors
with the aim of developing analgesic and antihypertensive agents that act by preventing neprilysin 's activity against signaling peptides such as enkephalins , substance P , endothelin , and atrial natriuretic factor.[11][12(passive) have been designedInhibitors
medicinal chemistsdesigningprotease inhibitors
to limit the effects of a cell structure called a proteasome(passive) are designedProteasome inhibitors
to inhibit the HIV protease enzyme which is essential for the production and cleavage of mature infective virions(passive) are designedProtease inhibitors
in the past(passive) have been designedInhibitors
against the AIDS virusdesignedagainst the AIDS virus
for use against the hepatitis C virusare designedfor use against the hepatitis C virus
for the treatment of hepatitis C virusdiscoveredfor the treatment of hepatitis C virus
the hiv virus from constructing proteins itpreventthe hiv virus from constructing proteins it
the HIV virus from replicating inside the bodypreventthe HIV virus from replicating inside the body
to prevent the HIV virus from replicatingdesignedto prevent the HIV virus from replicating
proteolytic cleavage of a final product necessary for assembly and release of the viruspreventsproteolytic cleavage of a final product necessary for assembly and release of the virus
extracellular matrix protein degradationto preventextracellular matrix protein degradation
Using Generative Deep Learning Approaches " DOIDesignedUsing Generative Deep Learning Approaches " DOI
to block an enzyme that helps the hepatitis C virus replicatedesignedto block an enzyme that helps the hepatitis C virus replicate
to block an enzyme that the hepatitis C virus requires to replicatedesignedto block an enzyme that the hepatitis C virus requires to replicate
to specifically inhibit the aspartic protease of HIV-1designedto specifically inhibit the aspartic protease of HIV-1
the serine protease enzymepreventthe serine protease enzyme
the protease enzyme from producing mature virions of the viruspreventingthe protease enzyme from producing mature virions of the virus
viral replication selectively binding to viral proteases ( e.g. HIV-1 proteasepreventviral replication selectively binding to viral proteases ( e.g. HIV-1 protease
proteolytic cleavage of proteins ( table 2preventproteolytic cleavage of proteins ( table 2
in impaired breakdown of all proteins in the gut at that timeresultin impaired breakdown of all proteins in the gut at that time
digestion of the proteins in the Chickpeapreventdigestion of the proteins in the Chickpea
proteases cutting up the proteinspreventproteases cutting up the proteins
the development of human rotavirus - induced diarrhea in suckling micepreventthe development of human rotavirus - induced diarrhea in suckling mice
to the development of a leaky gutmay contributeto the development of a leaky gut
hyperglycemia and insulin resistance ) saxagliptin + tipranavirmax saxagliptin dose 2.5 mg / daycausehyperglycemia and insulin resistance ) saxagliptin + tipranavirmax saxagliptin dose 2.5 mg / day
hyperglycemia and insulin resistance ) saxagliptin + atazanavirmax saxagliptin dose 2.5 mg / daycausehyperglycemia and insulin resistance ) saxagliptin + atazanavirmax saxagliptin dose 2.5 mg / day
hyperglycemia and insulin resistance ) saxagliptin + saquinavirmax saxagliptin dose 2.5 mg / daycausehyperglycemia and insulin resistance ) saxagliptin + saquinavirmax saxagliptin dose 2.5 mg / day
hyperglycemia and insulin resistance ) saxagliptin + indinavirmax saxagliptin dose 2.5 mg / daycausehyperglycemia and insulin resistance ) saxagliptin + indinavirmax saxagliptin dose 2.5 mg / day
hyperglycemia and insulin resistance ) saxagliptin + nelfinavirmax saxagliptin dose 2.5 mg / daycausehyperglycemia and insulin resistance ) saxagliptin + nelfinavirmax saxagliptin dose 2.5 mg / day
to lipodystrophy which can lead to elevated blood glucose because of Insulin resistancecan contributeto lipodystrophy which can lead to elevated blood glucose because of Insulin resistance
the enzyme proteasepreventthe enzyme protease
to keep the virus from reproducing by disabling a crucial enzymeare designedto keep the virus from reproducing by disabling a crucial enzyme
the virus from maturing properly once they egresspreventthe virus from maturing properly once they egress
protein digestion in the intestinepreventprotein digestion in the intestine
hyperglycemia and insulin resistance ) insulin Kombiglyze XRcausehyperglycemia and insulin resistance ) insulin Kombiglyze XR
hyperglycemia and insulin resistance ) atenolol Janumet XRcausehyperglycemia and insulin resistance ) atenolol Janumet XR
hyperglycemia and insulin resistance ) lurasidone Janumet XRcausehyperglycemia and insulin resistance ) lurasidone Janumet XR
to block HIV viral replication and have been around for more than 10 yearsdesignedto block HIV viral replication and have been around for more than 10 years
or reduce the incidence of transformation and reduce the metastatic potential of cancer cellsmay preventor reduce the incidence of transformation and reduce the metastatic potential of cancer cells
the activation of the complement systemcan influencethe activation of the complement system
the cleavage of HIV-1 Gagpreventthe cleavage of HIV-1 Gag
degradation of proteinspreventdegradation of proteins
more body shape problems than Sustivacausemore body shape problems than Sustiva